AUTHORS
Bingjie Ding, Fengdi Wang2, Xuewen Song, PhD3, Mengjuan Li4, Junxia Hu5, Hu Zhou, MD6
AFFILIATIONS
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
4 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
5 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
6 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
ABSTRACT
Objective: Despite the efficacy of thrombopoietin receptor agonists (TPO-RAs) in milder cancer therapy-induced thrombocytopenia (CTIT), refractory severe cases (grade 4, platelets <25×10?/L) remain an unmet need with no standard therapy, partly due to immune dysregulation and bone marrow (BM) microenvironment damage. Low-dose decitabine, a hypomethylating agent with immunomodulatory and niche-repairing properties, may synergize with TPO-RAs. This study aimed to evaluate the efficacy, safety, and prognostic factors of combining low-dose decitabine with TPO-RAs in refractory severe CTIT.
Methods: This retrospective cohort study included 96 patients with persistent CTIT who received low-dose decitabine (3.5 mg/m²/day ×3 days/cycle, ≥3 cycles) plus a TPO-RA (eltrombopag, hetrombopag, avatrombopag, romiplostim, or rhTPO) between January 2019 and April 2025. Efficacy was assessed at weeks 4, 8, 12, and 24. Response (R) was defined as platelets ≥50×10?/L, significant response (SR) as ≥75×10?/L, and complete response (CR) as ≥100×10?/L, confirmed by two consecutive measurements. Multivariate logistic regression identified predictive factors. Safety was graded by CTCAE v5.0.
Results: The cohort (median age 54.5 years, 52.1% male) had a median baseline platelet count of 9.5×10?/L (range 1–34×10?/L) and a median bone marrow megakaryocyte count of 38 (range 1–885); 79.2% had hypercellular marrow. Remarkably, 97.9% had previously failed TPO-RA monotherapy. The R rates at weeks 4, 8, 12, and 24 were 57.3% (55/96), 73.7% (70/95), 80.0% (76/95), and 83.1% (54/65), respectively; SR rates were 36.5% (35/96), 57.9% (55/95), 64.2% (61/95), and 72.3% (47/65); CR rates were 24.0% (23/96), 38.9% (37/95), 41.1% (39/95), and 35.4% (23/65). Median time to R was 21 days (range 7–147), to SR 35 days (14–147), and to CR 42 days (14–168); median response durations were 140, 126, and 98 days, respectively. Multivariate analysis revealed dynamic predictors: at week 4, baseline platelet count was the strongest factor (OR 1.13–1.29, all P<0.05). At week 8, CD3? T-cell proportion (OR 1.15–1.17), BM megakaryocyte count (OR 1.018–1.04), and number of decitabine cycles (OR 6.17–9.60) independently predicted R and SR (all P<0.05); BM hypercellularity also predicted SR (OR 0.006, P=0.011). By weeks 12 and 24, the number of decitabine cycles became the predominant factor for SR and CR, with ORs up to 86.9 (P=0.022) and 32.3 (P=0.013), respectively, and BM hypercellularity predicted CR at week 24 (OR 0.033, P=0.042). Subgroup analysis showed that patients with BM metastasis had a dismal response (only 12.5% achieved R), whereas no significant efficacy differences were observed among eight different TPO-RA combinations after Bonferroni correction (adjusted α=0.0018), indicating a class effect. Safety was favorable: most adverse events were grade 1–2, including hepatic dysfunction (9.4%), venous thromboembolism (VTE, 8.3%), leukopenia (7.3%), neutropenia (5.2%), and anemia (4.2%). No grade 3–4 myelosuppression, treatment-related discontinuations, or unexpected severe toxicities occurred. The VTE rate remained within the expected cancer background range (4–20%).
Conclusion: Low-dose decitabine combined with TPO-RAs offers robust, rapid, and durable platelet recovery with a favorable safety profile in refractory severe CTIT, even in patients who have failed prior TPO-RA therapy. Baseline platelet count, BM megakaryocyte reserve, T-cell subsets, BM cellularity, and cumulative decitabine cycles serve as valuable prognostic indicators. This combination represents a promising novel strategy and warrants prospective validation.
DISCLOSURES
Bingjie Ding: No relevant conflicts of interest to declare.